+ All Categories
Transcript
Page 1: Epilepsy: Challenges & Therapies Orrin Devinsky, M.D. NYU Epilepsy Center.

Epilepsy: Challenges & Epilepsy: Challenges & TherapiesTherapies

Orrin Devinsky, M.D.NYU Epilepsy Center

Page 2: Epilepsy: Challenges & Therapies Orrin Devinsky, M.D. NYU Epilepsy Center.

Diagnostic ChallengesDiagnostic Challenges

Define epilepsy syndrome Video-EEG monitoring

Understand the cause of epilepsy High resolution MRI Genetic studies (GEFS+, Chromosomal microarrays)

Define factors that provoke seizures FAILURE

Identify long-term effects of epilepsy &s its treatment

Page 3: Epilepsy: Challenges & Therapies Orrin Devinsky, M.D. NYU Epilepsy Center.

Therapeutic ChallengesTherapeutic Challenges

No seizures, no side effects If patients had their choice:

No doctors, No Medicines In general, would rather see doctor than take medication

Page 4: Epilepsy: Challenges & Therapies Orrin Devinsky, M.D. NYU Epilepsy Center.

Therapeutic ChallengesTherapeutic Challenges

Ongoing assessment: consequences of seizures and therapy

How aggressive to pursue seizure control?

Do we treat interictal EEG? ? Benign rolandic epilepsy

How to assess effects of long-term therapies?

Page 5: Epilepsy: Challenges & Therapies Orrin Devinsky, M.D. NYU Epilepsy Center.

Alternative Therapies for Alternative Therapies for EpilepsyEpilepsy

Diverse group Osteopathy, chiropractic, homeopathy, herbs, EEG feedback (neurotherapy), stress reduction, magnetic stimulation, carbon dioxide therapy, fatty acids

We need data!

Page 6: Epilepsy: Challenges & Therapies Orrin Devinsky, M.D. NYU Epilepsy Center.

Common Errors that Common Errors that Doctors MakeDoctors Make

Misdiagnosis Is it epilepsy? Which epilepsy syndrome? Not noticing change

Incorrect medication choice AEDs can exacerbate seizures

Failure to reassess orconsider VNS or surgery

Page 7: Epilepsy: Challenges & Therapies Orrin Devinsky, M.D. NYU Epilepsy Center.

Mistakes I’ve Made Mistakes I’ve Made

Relying on prior diagnosis Becoming “invested” in a course of action

Not listening to the information Not challenging one’s own conclusion Finding information that supports Explaining information that doesn’t fit

Page 8: Epilepsy: Challenges & Therapies Orrin Devinsky, M.D. NYU Epilepsy Center.

Physician Issues in Physician Issues in Selecting AED Selecting AED

AED relative efficacy:toxicity Knowledge

Published studies Randomized v. open-label Dose range, methodology Statistical v. clinical significance

Information from colleagues Personal experience Belief, Bias, & Comfort Zone

Page 9: Epilepsy: Challenges & Therapies Orrin Devinsky, M.D. NYU Epilepsy Center.

Quality of Life: Quality of Life: The Traditional ViewThe Traditional View

Medical Education - MD perspective Medical literature, clinical experience

Disorders - signs & symptoms Evaluation - history, PE, Lab Therapy - studies of medical outcome

Page 10: Epilepsy: Challenges & Therapies Orrin Devinsky, M.D. NYU Epilepsy Center.

QOL: QOL: A Different ViewA Different View

QOL - Defined by patient not MD Should patient’s perspective be filtered through “objective medical lens”? - NO

QOL is about listening, changing perspective, and using the patients’ view as the ultimate measure of outcome

Page 11: Epilepsy: Challenges & Therapies Orrin Devinsky, M.D. NYU Epilepsy Center.

QOL: QOL: Relevance to Relevance to Epilepsy?Epilepsy?

QOL issues most relevant to chronic disorders, problems beyond disease symptoms

Epilepsy is the paradigm of such a disorder

Seizures are infrequent,AED effects & psychosocial problems are chronic

Page 12: Epilepsy: Challenges & Therapies Orrin Devinsky, M.D. NYU Epilepsy Center.

A Case StudyA Case Study

29 y.o. woman monthly CPS, rare GTCs Routine 6 mo. Checkup: complains of some tiredness, blurred vision, nausea

Exam - mild nystagmus, tremor Labs - slightly elevated LFTs

MD’s perspective - doing great Woman’s perspective - doing poorly; not driving, underemployed, fearful of seizures, troubled by AEs

Page 13: Epilepsy: Challenges & Therapies Orrin Devinsky, M.D. NYU Epilepsy Center.

Cognitive & Cognitive & Behavioral Changes Behavioral Changes

in Epilepsyin Epilepsy Must diagnose to treat Cognitive-behavioral disorders are often overlooked - “under appreciated” Not spontaneously reported Not asked about by MD/RN Noted, but considered minor Noted, but considered untreatable

Page 14: Epilepsy: Challenges & Therapies Orrin Devinsky, M.D. NYU Epilepsy Center.

Seizure Burden: Seizure Burden: The Great LieThe Great Lie

Are complex partial seizures bad? Memory - long-term consequences Personality changes Affective changes Psychosis

Are tonic-clonic seizures bad? You bet!

Page 15: Epilepsy: Challenges & Therapies Orrin Devinsky, M.D. NYU Epilepsy Center.

PGE and Behavior:Absence Epilepsy (Wirrell et al, 1997)

56 absence epilepsy v. 61 JRA patient Pts with absence epilepsy had more academic, personal, and behavioral disorders (p<.001)

Those with ongoing seizures had worse outcomes

Page 16: Epilepsy: Challenges & Therapies Orrin Devinsky, M.D. NYU Epilepsy Center.

Epilepsy: Epilepsy: Progressive Progressive

Cognitive DeclineCognitive Decline Tuberous Sclerosis (Gomez)

Relation of Seizure and MR Of 140 pts with Szs - 89 MR Of 19 pts w/o Szs - none MR Age of seizure onset and MR related:

MR in 72/79 with seizures before age 1y MR in 6/25 with seizures after age 4 y

? Role of CNS pathology vs. Seizures ? Younger brain protected or at risk

Page 17: Epilepsy: Challenges & Therapies Orrin Devinsky, M.D. NYU Epilepsy Center.

Issues with AED Issues with AED SafetySafety

Idiosyncratic AE’s Dose-related AE’s

Cognitive Behavioral Quality of life

Chronic AE’s Teratogenic AE’s Drug interactions

Page 18: Epilepsy: Challenges & Therapies Orrin Devinsky, M.D. NYU Epilepsy Center.

Uncommon Side Uncommon Side EffectsEffects

Increased frequency of urination - lamotrigine

High blood pressure, migraines - carbamazepine

Aggressiveness - phenobarb, ethosuximide, levetiracetam

Severe sedation, coma - valproic acid Movement disorders - phenytoin, carbamazepine

Kidney stones - topiramate, zonisamide, acetazolamide

Page 19: Epilepsy: Challenges & Therapies Orrin Devinsky, M.D. NYU Epilepsy Center.

Getting Off AEDsGetting Off AEDs Everyone’s goal Must balance risk - benefit

Lifestyle factors such as driving Potential side effects How long do you wait for seizure freedom Do you ever try when EEG has spikes or sharp waves, or if auras/minor seizures persist

Middle road is often reasonable - gradual taper over months or often years

Page 20: Epilepsy: Challenges & Therapies Orrin Devinsky, M.D. NYU Epilepsy Center.

Chronic Adverse Chronic Adverse Effects: Effects:

Bone DisordersBone Disorders Decrease Ca/Vit D levels

CBZ (?OXC), PRM, PB, PHT, VPA New AEDs appear safer, but ?

Risk factors Dose, polytherapy, & duration

Diagnosis Suspicion; bone densitomety

Treatment - Vit D/Ca, sun, alendrodate, estrogen supp after menopause

Page 21: Epilepsy: Challenges & Therapies Orrin Devinsky, M.D. NYU Epilepsy Center.

Rapist RoostersRapist RoostersGrandin - Animals in Grandin - Animals in

TranslationTranslation Observed chicken pecked to death

Chicken farmer - we see this; roosters rape and murder, lots of them

Breeding for single traits Large breasts & rapid growth Roosters lost their mating dance

We get used to abnormal, and think its normal

Page 22: Epilepsy: Challenges & Therapies Orrin Devinsky, M.D. NYU Epilepsy Center.

Long Term Side Long Term Side Effects: Effects:

? Drugs v. Disease ? Drugs v. Disease v. Person v. Person

After several years, hard to determine if something really exists - ? personality/person versus disease process versus AED

Can be impossible to determine Reducing or changing drugs may be only way to answer, but may be dangerous

Young woman, PB, and memory

Page 23: Epilepsy: Challenges & Therapies Orrin Devinsky, M.D. NYU Epilepsy Center.

DepressionDepression

Common Underdiagnosed Undertreated

Doctors and patients are at fault Major factor in reducing quality of life

Polycystic ovarian syndrome

Page 24: Epilepsy: Challenges & Therapies Orrin Devinsky, M.D. NYU Epilepsy Center.

Depression and QOL in Epilepsy

Beck Depression Inventory Score

4035302520151050-5

QO

LIE

-89

Tot

al S

core

100

80

60

40

20

0

Depression (SCL-90-R)

90807060504030

Tot

al Q

OL

IE-8

9

70

60

50

40

30

20

Johnson et al.,2004

Gilliamet al., 2002

Crameret al, 2003

CES-D

706050403020100

QO

LIE

-31

100

80

60

40

20

00

10

20

30

40

50

60

70

80

90

100

-5 0 5 10 15 20

25 30 35 40 45 50

Depression (BDI)

Qua

lity

of L

ife (

QO

LIE

-31)

Boylan et al., 2004

Page 25: Epilepsy: Challenges & Therapies Orrin Devinsky, M.D. NYU Epilepsy Center.

Sudden Unexplained Sudden Unexplained Death in Epilepsy Death in Epilepsy

(SUDEP)(SUDEP) SUDEP incidence increases with epilepsy severity Community sample -- 0.35/1000 pt-yrs

24X general populate rate Epilepsy centers -- 1.0/1000 pt-yrs

AED/VNS trials -- 3.75/1000 pt-yrs

Page 26: Epilepsy: Challenges & Therapies Orrin Devinsky, M.D. NYU Epilepsy Center.

0 25 50 75 100 125 150 175 200

Annual incidence per 10,000 population

Sudden Unexplained Sudden Unexplained Death Death in Epilepsy (SUDEP)in Epilepsy (SUDEP)General population (2–3)

Epilepsy incidence population (5)

Epilepsy prevalence population (7)

Patients in clinical trials (30–50)

Patients undergoing vagus nerve stimulation (41)

Patients referred to epilepsy centers (50–60)

Surgical candidates (90)

Surgical failures (150)

Page 27: Epilepsy: Challenges & Therapies Orrin Devinsky, M.D. NYU Epilepsy Center.

Developmental Developmental Disabilities & Disabilities &

EpilepsyEpilepsy Never lose sight of the person behind the frail frame or cognitive impairment

Put yourself in their shoes We relate to those like us Teachers favor good looking students, what of doctors?

Lower expectations Don’t tolerate side effects, seizures, lower QOL

Neurologic disorders close doors of normality, but open new ones

Page 28: Epilepsy: Challenges & Therapies Orrin Devinsky, M.D. NYU Epilepsy Center.

New Therapies in New Therapies in Epilepsy:Epilepsy:

AED PipelineAED Pipeline Novel mechanisms

Potassium channels - retigabine, Functionalized amino acid (glycine; NMDA antagonist)

- lacosamide GABAA receptor modifiers - neuroctive steroid

(ganaxalone) New Relatives of known drugs

Synaptic vesical 2A ligands (levetericetam relatives)

Sodium channel - oxcarbazepine relative Valproate relatives - valrocamide, isovaleramide Felbamate relative - flourofelbamate

Nasal midazolam - new rescue medication! More rapid onset, quicker offset than rectal

diazepam

Page 29: Epilepsy: Challenges & Therapies Orrin Devinsky, M.D. NYU Epilepsy Center.

Closing ThoughtsClosing Thoughts Health care is a partnership

Knowldege is power Communication is essential QOL is yours

Never accept seizures and side effects

The future has never been better


Top Related